Oncocross Decides to Merge with OncoMASTER, Issuing 850,397 New Shares... No Change in Major Shareholder but Dilution and Synergy Anticipated
Oncocross has decided to absorb unlisted OncoMASTER, issuing 850,397 new shares at a merger ratio of 1:5.2100960. This represents approximately 6.97% dilution relative to the existing 12,195,957 outstanding shares, and the new shares will be under a 1-year lock-up restricting immediate sale.
The purpose of the merger is to accelerate the development of AI drug discovery platform ONCO-RAPTOR and early cancer diagnosis solution ONCOfind by utilizing OncoMASTER's cancer patient cohort data. Integration of data and human resources is expected to generate mid-to-long-term financial and operational synergies.
After the merger, CEO Kirang Lee's stake will slightly decrease from 16.83% to 15.73%, but he will remain the largest shareholder. The merger is structured as a small-scale merger, so Oncocross shareholders do not have appraisal rights; it can be blocked if shareholders holding 20% or more oppose.
OncoMASTER's major shareholders include Yuhan Corporation and Korea University Technology Holdings, providing some counterparty credibility. External appraiser Ichon Accounting Firm confirmed the merger ratio is within the fair range.
[AI Summary]Oncocross's merger with OncoMASTER is strategically aimed at acquiring data to enhance its AI platform, but the ~7% dilution poses a short-term burden for existing shareholders. Long-term synergies could enhance corporate value, but the target's negative equity and persistent losses introduce integration risks. Investors must weigh synergy potential against dilution impact.
KOSDAQ Filing Information
[Correction of Description] Report On Major Matters (Decision On Company Merger)